CA-IKOTEK
29.9.2022 15:01:38 CEST | Business Wire | Press release
Ikotek, the leading IoT original design manufacturer (ODM) and electronics manufacturing service (EMS) provider, is announcing expansion of its executive management team with industry veterans and continue their aggressive growth plans for the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005870/en/
Ikotek - Your Trusted IoT ODM Partner (Photo: Business Wire)
Headquartered in San Diego, USA, Ikotek offers a one-stop-shop for IoT solutions across design and development, hardware build, testing and verification, product validation, software development, manufacturing and certification delivering high quality products and services to reduce complexity, speed up time to market, eliminate risk and reduce costs. The company has already designed, manufactured and shipped millions of IoT devices since its inception.
Ikotek, the only US-based global ODM with a pure IoT focus, combines end-to-end design consultancy across program management, R&D, sourcing, testing and production at its own as well as third party manufacturing facilities to produce designs for our customers. With a wide variety IoT projects in progress, such as asset tracking, dash cameras, PDAs and handhelds, point of sale (POS) devices and hardware for smart grid and metering deployments, Ikotek’s core focus is on the enterprise market as it looks to develop solutions to take full advantage of IoT at scale.
Led by Chief Executive Officer, Joe Peterson, who has more than 27 years of diverse experience across cellular and IoT industries in the US and international, Ikotek has gathered a team of industry veterans to amplify its vision of becoming the world’s most trusted IoT ODM. Recent additions to the US-based executive management team include:
Bill Leunis, the Vice President of Finance, who brings extensive experience in finance, operations and general management in manufacturing and EMS organizations. Previously, he has headed Finance in divisions of large multi-national corporations ranging in size from 500 to 20,000 people. In addition, he has served as CFO of a company, leading all aspects from its acquisition to IPO for eight years after going public.
Tim Newberg, the Vice President of Sales for the US and Canada, has joined with more than 25 years of experience and leadership in the wireless, broadband, consumer electronics and massive IoT industries. From hardware and software strategy to product marketing, sales and business development he has held senior executive positions at companies including Texas Instruments, Broadcom, Sequans, Rootmetrics, Polte and Sercomm.
Steve Burrington, the Head of North America Engineering, is a 25-year veteran of large and medium-sized wireless product development teams. Previously he served as Vice President of Engineering at CalAmp for the company’s telematics products. He has extensive experience of getting a diverse range of products to market, via organic development and JDM partnerships. In addition, he has held Vice President of Engineering roles at Netgear and Sierra Wireless.
These additions to the Ikotek management team have been supported by hires across the business and Ikotek now has more than 350 dedicated R&D employees and continues to add employees on a weekly basis.
“We’ve seen an incredible uptake of new customers over the last year and we’re excited to bring our unique ODM capabilities and advantages to customers,” said Peterson. “Supporting our customers with quick time-to-market, leading IoT industry expertise and cost-effective services and solutions is critical during a time where digital transformation is growing across all industries. To help manage growth, commercial excellence and new customers, I’m thrilled to welcome these three leading IoT and ODM capacities to our management team. We aim to serve our customers with local experts in North America and Europe and APAC so we can ensure that Ikotek is close to our customers and has local understanding of their needs.”
Ikotek targets mid-market IoT customers in response to increased demand for the design and build of products. The company’s ethos is to give customers a competitive advantage, through cost reductions and enable substantial savings to be achieved on their device design, manufacturing and certification costs. In addition, Ikotek is focused on taking customers’ projects from idea to market in record breaking time. In less than three months, Ikotek has provided end-to-end ODM services that took a complex IoT device to market including design, development and manufacturing.
“Ikotek exists to turn our customers’ device dreams into IoT reality,” Peterson added, pointing out the ways in which the company can help are listed on www.ikotek.com. “We’re keen to become customers’ indispensable partner in taking their innovations from concept to high volume product launches across global markets.”
About Ikotek
Ikotek is The IoT ODM. With a wide variety IoT projects currently underway, our core focus is on the enterprise market as it looks to develop solutions to take full advantage of IoT. We cover technologies from cellular connectivity, including NB-IoT and 5G, to satellite connections and from well-established IT to relative newcomers such as artificial intelligence IoT (AIoT).
For more information: www.ikotek.com LinkedIn
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220928005870/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
